Revenue Projections - The company expects 2024 annual revenue to be between 2.1 billion and 2.3 billion CNY, an increase of 161.73 million to 361.73 million CNY, representing a year-on-year growth of 8.34% to 18.66%[4]. - In 2023, the company achieved a total profit of 506.27 million CNY and revenue of 1.938 billion CNY[7]. Profit Projections - The projected net profit attributable to shareholders for 2024 is expected to be between 180 million and 220 million CNY, a decrease of 229.06 million to 269.06 million CNY, reflecting a year-on-year decline of 51.01% to 59.92%[4]. - The estimated net profit attributable to shareholders after deducting non-recurring gains and losses for 2024 is expected to be between 170 million and 210 million CNY, a decrease of 228.09 million to 268.09 million CNY, indicating a year-on-year decrease of 52.07% to 61.20%[4]. - The net profit attributable to shareholders in 2023 was 449.06 million CNY, with a net profit after deducting non-recurring gains and losses of 438.09 million CNY[7]. Market and Operational Insights - The company anticipates continued growth in product sales in 2024, responding to market demand and competition[8]. - Increased operational scale has led to higher related expenses compared to the previous year, impacting overall profit[8]. - The price of valine products has decreased due to intensified market competition, affecting the company's profitability[8]. Forecast Accuracy - There are no significant uncertainties affecting the accuracy of this earnings forecast[9]. - The forecast data is preliminary and subject to final confirmation in the official 2024 annual report[10].
华恒生物(688639) - 2024 Q4 - 年度业绩预告